229961-22-2

Upstream product

• 51934-41-9 4-iodobenzoic acid ethyl ester 
• 229961-91-5 6-ethynyl-2,2,-dimethylthiochroman-4-one 
• 111424-46-5 3-(4-methoxy-phenylsulfanyl)-3-methyl-butyric acid 
• 619-58-9 4-iodobenzoic acid 
• 60-29-7 diethyl ether 
• 229961-88-0 6-hydroxy-2,2-dimethyl-thiochroman-4-one 
• 111424-51-2 6-methoxy-2,2-dimethyl-thiochroman-4-one 
• 541-47-9 3-Methylbutenoic acid 
• 696-63-9 4-Methoxybenzenethiol 
• 229961-90-4 2,2-dimethyl-6-trimethylsilanyl-ethynyl-thiochroman-4-one 
• 229961-89-1 2,2-dimethyl-4-oxo-thiochroman-6-yl trifluoromethanesulfonate 

Downstream Products

• 229961-23-3 ethyl 4-((2,2-dimethyl-4-trifluorosulfonyloxy-(2H)-thiochromen-6-yl)ethynyl)-benzoate 
• 229961-29-9 ethyl 4-<<4-(4-tert-butylphenyl)-2,2-dimethyl-(2H)-thiochromen-6-yl>ethynyl>-benzoate 
• 229961-32-4 ethyl 4-<<4-(5-tert-butyl-thiophen-2-yl)-2,2-dimethyl-(2H)-thiochromen-6-yl>ethynyl>-benzoate 
• 229961-28-8 ethyl 4-<<4-(4-isopropylphenyl)-2,2-dimethyl-(2H)-thiochromen-6-yl>ethynyl>-benzoate 
• 229961-27-7 ethyl 4-<<4-(4-ethylphenyl)-2,2-dimethyl-(2H)-thiochromen-6-yl>ethynyl>-benzoate 
• 229961-31-3 ethyl 4-<<4-(5-ethyl-thiophen-2-yl)-2,2-dimethyl-(2H)-thiochromen-6-yl>ethynyl>-benzoate 
• 229961-26-6 ethyl 4-<<4-(4-methylphenyl)-2,2-dimethyl-(2H)-thiochromen-6-yl>ethynyl>-benzoate 
• 229961-45-9 VTP 194310 
• 229961-33-5 ethyl 4-<<4-(6-methyl-pyridin-3-yl)-2,2-dimethyl-(2H)-thiochromen-6-yl>ethynyl>-benzoate 
• 229961-30-2 ethyl 4-<<4-(5-methyl-thiophen-2-yl)-2,2-dimethyl-(2H)-thiochromen-6-yl>ethynyl>-benzoate 
• 229961-24-4 ethyl 4-<<4-phenyl-2,2-dimethyl-(2H)-thiochromen-6-yl>ethynyl>-benzoate 

Relevant academic research and scientific papers

EXPANSION OF RENEWABLE STEM CELL POPULATIONS

Ex vivo and in vivo methods of expansion of renewable stem cells, expanded populations of renewable stem cells and their uses.

METHODS FOR TREATING CHEMOTHERAPY AND RADIATION THERAPY SIDE EFFECTS

A method for treating chemo therapy or radiation therapy side effects in a mammal undergoing chemotherapy and/or radiation therapy, the method comprising a step of administering to the mammal a therapeutically effective amount of a RAR antagonist or RAR i

Methods of treatment during vascular procedures

The invention provides in one embodiment a method for treating vascular trauma. The method can include administering to an individual undergoing vascular trauma an effective amount of a retinoic acid receptor (RAR) antagonist or an RAR inhibitor. The meth

Methods of treating hyperlipidemia

The current invention relates to methods for treating hyperlipidemia in mammals, including humans. More specifically, the current invention relates to the use of retinoid or retinoid derivative that is able to act as an antagonist or inverse agonist of a

SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES

2,2-Dialkyl-4-aryl-substituted benzopyran and benzothiopyran derivatives of the formula STR1 where the symbols have the meaning described in the specification, have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists.

Synthesis and biological activity of high-affinity retinoic acid receptor antagonists

This article reports the synthesis and biological activity of new high affinity retinioic acid receptor (RAR) antagonists. The effect of introducing heteroatoms in the bicyclic ring system of the potent dihydronaphthalene RAR antagonist 8, and the variation of the pendant aromatic group on the ability of these compounds to function as RAR antagonists is discussed. The use of binding, transcriptional, and in vivo assays revealed that the 2,2-dimethylthiochromene analogue 59, and the 2,2-dimethylchromene derivative 85, were the most effective in blocking retinoid agonist induced activity. Copyright (C) 1999 Elsevier Science Ltd.